Skip to main content
Fig. 3 | BMC Ophthalmology

Fig. 3

From: Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial

Fig. 3

Mean change in BCVA from baseline to the last visit by baseline ischemia. BCVA, best corrected visual acuity; IVR, intravitreal ranibizumab; General linear models were constructed for variance analysis with baseline BCVA adjusted, mean gains in BCVA from baseline to week 52 were similar between two groups in patients with ischemia (P = 0.9830) or without ischemia at baseline (P = 0.5050). Change in BCVA from baseline to week 52 in patients with or without ischemia were normally distributed (all P > 0.05 in Shapiro-Wilk tests). Mean ± SD change in BCVA from baseline to week 52 in patients with ischemia was 16.3 ± 10.3 letters in IVR group, 17.5 ± 8.8 letters in IVR + Laser group. Mean ± SD change in BCVA at week 52 from baseline in patients without ischemia was 18.8 ± 8.2 letters in IVR group, 18.7 ± 11.0 letters in IVR + Laser group

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us